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 I read with interest the article titled “Target Sign: 
Endoscopic Sign of the Colonic Perforation” by Costa 
JM et al.1 It is indeed unfortunate when a well-intended 
therapeutic intervention results in iatrogenic complications. 
Indeed, the early recognition of target sign as a marker of 
colonic perforation will enable the immediate closure of the 
defect by endoscopic clips.
 The European Society of Gastrointestinal Endoscopy 
position statement in 2014 recommends clipping either 
through the scope or over the scope within four hours of 
colonic perforation, depending on the size of the defect.2 
Post-procedure, the patients should be admitted and 
closely observed. If patients remain asymptomatic, they 
can be discharged with a prescription of oral antibiotics. 
However, symptomatic patients will require further imaging 
with computed tomography and possibly even a surgical 
repair.2
 As compared to a very high perforation rate of up to 15% 
due to acute diverticulitis, colonoscopy related perforation 
occurs at rates not exceeding 1%.3 Risk factors for colonic 
perforation includes advancing age, presence of pre-
disposing conditions such as peptic ulcer disease and acute 
appendicitis, poor nutritional status, the primary cause of 
the perforation (i.e. either organic versus iatrogenic) and 
presence of other complications.4
 Therefore, the need for extra vigilance for complications 
of therapeutic procedures such as colonoscopy cannot be 
overemphasized with a proactive search for early signs of 
bleeding and perforation.5 After all, “the eyes can’t see what 
the mind doesn’t know.”
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 We have read with great interest the article published 
by Rocha et al1 about the prevalence of hepatitis A among 
Portuguese travelers, where the authors highlight the ten-
dency of lower rates of anti-Hepatitis A virus (HAV) anti-
body in Portuguese adults up to 50 years old. In fact, this 
is a confirmation of a tendency that was firstly observed 20 
years ago when a study by Marinho et al2 demonstrated this 
difference: the prevalence in healthcare workers (average 
age of 40.1 years) was 86.4% in opposition to a prevalence 
of 35,3% in medical students (average age of 20.7 years). 
This is quite different from the figures encountered around 
a decade before, in 1984, in the largest study on hepatitis A 
prevalence in Portugal: 84.9% in overall population, 23.6% 
in those under 4 years of age, increasing to 93.6% by 18 
and reaching 99% after the age of 30.3
 We have also conducted a study where this same trend 
was detected, and verified that it is not that recent. We ret-
rospectively reviewed the anti-HAV antibodies (IgG, and 
IgM when it was asked) of all patients to whom it was re-
quested at our district Hospital - either in the Emergency 
Department, the Ward or Consultation - which encompass 
a heterogeneous population, in the years of 2004 and 2013, 
to check for any differences in this period of time. We in-
cluded 637 patients (296 in 2004 and 341 in 2013) with a 
median age of 41.2 ± 19.1 years (38.7 years in 2004 and 
43.4 in 2013) of which 55.7% were men. The mean preva-
lence of hepatitis A was 77.7% in 2004 and 76.2% in 2013 
(p = 0.66). On the other hand, the prevalence in the pedi-
atric age group was 34.8% in 2004 and 39% in 2013 (p = 
0.80). The only statistically significant difference we have 
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 I read with interest the recently published article by 
Rocha et al1 in your esteemed journal. As the authors 
mentioned, the prevalence of hepatitis A virus (HAV) 
infection decreased in young adults in Portugal and we 
have similar data from other parts of the world too.2,3 The 
prevalence of HAV infection differs greatly in various parts 
of the world depending on the geographic area, sanitary 
conditions and socioeconomic levels. There are several 
reports about a shifting epidemiological pattern of HAV 
from high prevalence to lower endemicity as a result of 
improved living conditions all over the world, even in 
developing countries.4 The most frequent travel destination 
in Rocha et al1 was sub-Saharan Africa and around 50% of 
travelers under 50 years old susceptible to hepatitis A virus 
infection required HAV vaccination before travelling to high 
endemicity areas for HAV infection. I would like to mention 
that nobody should forget the Middle East area with many 
conflicts such as wars, floods and crisis that can affect the 
access to safe water and proper disposal of wastes. The 
tourists from western countries with low endemicity for HAV 
infection should receive HAV vaccine and be more aware 
of good practices in safe water drinking in the Middle East 
region.3,5
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found was the mean age of patients with or without previous 
hepatitis A that was 46.2 and 24.1 years, respectively (p < 
0.05), which illustrates once again the lower prevalence in 
younger people, a fact that is also stressed in their article.1
 Nevertheless, there is a considerable difference in hep-
atitis A prevalence between our studies, which may be re-
lated to the various ethnicities of patients attended at our 
Hospital, since at least the mean age of patients in our stud-
ies is quite similar.
 Just like our colleagues, we share the concerns around 
the implications that this higher lack of immunity to hepatitis 
A could have in the nearby future.
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